KALA BIO Crecimiento futuro

Future controles de criterios 0/6

KALA BIO se prevé un crecimiento anual de los beneficios y los ingresos de 23.7% y 63%, respectivamente, mientras que el BPA aumentará de grow a 35.6%.

Información clave

25.8%

Tasa de crecimiento de los beneficios

36.4%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	19.3%
Tasa de crecimiento de los ingresos	61.3%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	02 Apr 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Previsiones de crecimiento de beneficios e ingresos

LSE:0JQ2 - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	25	-19	N/A	N/A	1
12/31/2025	N/A	-42	N/A	N/A	1
12/31/2024	N/A	-40	N/A	N/A	3
12/31/2023	N/A	-42	-29	-28	N/A
9/30/2023	N/A	-46	-35	-34	N/A
6/30/2023	0	-9	-47	-47	N/A
3/31/2023	3	-26	-65	-65	N/A
12/31/2022	4	-45	-79	-79	N/A
9/30/2022	6	-80	-93	-93	N/A
6/30/2022	8	-137	-104	-103	N/A
3/31/2022	9	-145	-100	-100	N/A
12/31/2021	11	-143	-109	-108	N/A
9/30/2021	12	-126	-108	-106	N/A
6/30/2021	11	-126	-107	-106	N/A
3/31/2021	9	-113	-105	-103	N/A
12/31/2020	6	-104	-93	-91	N/A
9/30/2020	5	-95	-85	-83	N/A
6/30/2020	5	-90	-82	-80	N/A
3/31/2020	6	-91	-83	-81	N/A
12/31/2019	6	-94	-94	-93	N/A
9/30/2019	5	-98	-93	-90	N/A
6/30/2019	3	-90	-86	-84	N/A
3/31/2019	1	-81	-74	-73	N/A
12/31/2018	N/A	-67	-56	-54	N/A
9/30/2018	N/A	-53	-46	-45	N/A
6/30/2018	N/A	-47	-39	-38	N/A
3/31/2018	N/A	-44	-38	-37	N/A
12/31/2017	N/A	-42	-35	-34	N/A
9/30/2017	N/A	-39	N/A	-35	N/A
6/30/2017	N/A	-39	N/A	-34	N/A
3/31/2017	N/A	-38	N/A	-32	N/A
12/31/2016	N/A	-33	N/A	-27	N/A
9/30/2016	N/A	-30	N/A	-24	N/A
6/30/2016	N/A	-25	N/A	-19	N/A
3/31/2016	0	-18	N/A	-16	N/A
12/31/2015	0	-17	N/A	-15	N/A
9/30/2015	0	-17	N/A	-16	N/A
6/30/2015	0	-17	N/A	-17	N/A
3/31/2015	0	-18	N/A	-16	N/A
12/31/2014	0	-19	N/A	-15	N/A
12/31/2013	0	-11	N/A	-11	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: 0JQ2 se prevé que siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: 0JQ2 se prevé que siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: 0JQ2 se prevé que siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: 0JQ2 no tendrá ingresos el año que viene.

Ingresos de alto crecimiento: 0JQ2 no tendrá ingresos el año que viene.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la Rentabilidad de los fondos propios de 0JQ2 se prevé elevada dentro de 3 años.

Descubre empresas en crecimiento

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

KALA BIO Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

No longer forecast to breakeven

Recent updates

KALA BIO, Inc. announced that it expects to receive $8.599799 million in funding from Baker Bros. Advisors LP

KALA BIO, Inc. announced that it expects to receive $1.999824 million in funding

New major risk - Revenue size

First half 2023 earnings released: US$11.35 loss per share (vs US$41.26 loss in 1H 2022)

Kala Pharmaceuticals, Inc., Annual General Meeting, Jun 22, 2023

First quarter 2023 earnings released: US$6.99 loss per share (vs US$22.37 loss in 1Q 2022)

Full year 2022 earnings released: US$29.48 loss per share (vs US$109 loss in FY 2021)

Kala Pharmaceuticals, Inc. announced that it has received $30.999475 million in funding from Baker Bros. Advisors LP

Kala Pharmaceuticals, Inc. Announces FDA Acceptance of IND Application for KPI-012 for the Treatment of PCED

Kala Pharmaceuticals Receives Non-Compliance Notice From Nasdaq

Kala Pharmaceuticals, Inc. announced that it expects to receive $30.999475 million in funding from Baker Bros. Advisors LP

Kala Pharmaceuticals, Inc. Announces Appointment of Marjan Farid to Its Board of Directors

Insufficient new directors

Second quarter 2022 earnings released: US$0.38 loss per share (vs US$0.56 loss in 2Q 2021)

Kala Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Kala Pharmaceuticals Receives Non-Compliance Letter from Nasdaq

Alcon Pharmaceuticals Ltd and Alcon Vision, LLC completed the acquisition of EYSUVIS® and certain assets of Kala Pharmaceuticals, Inc. (NasdaqGS:KALA).

Insufficient new directors

Kala Pharmaceuticals Receives Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Alcon Inc. (SWX:ALC) entered into a agreement to acquire EYSUVIS® and certain assets of Kala Pharmaceuticals, Inc. (NasdaqGS:KALA) for $385 million.

Alcon Inc. (SWX:ALC) acquired EYSUVIS® from Kala Pharmaceuticals, Inc. (NasdaqGS:KALA) for $60 million.

First quarter 2022 earnings released: US$0.45 loss per share (vs US$0.49 loss in 1Q 2021)

Kala Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 16, 2022

Kala Pharmaceuticals to Present Clinical Data for KPI-012, its Mesenchymal Stem Cell Secretome Product, for the Treatment of PCED at the 2022 ARVO Annual Meeting

Kala Pharmaceuticals, Inc., Annual General Meeting, Jun 16, 2022

Insufficient new directors

Full year 2021 earnings released: US$2.19 loss per share (vs US$1.99 loss in FY 2020)

Insufficient new directors

Third quarter 2021 earnings released: US$0.43 loss per share (vs US$0.50 loss in 3Q 2020)

No longer forecast to breakeven

Second quarter 2021 earnings released: US$0.56 loss per share (vs US$0.42 loss in 2Q 2020)

Insufficient new directors

Insufficient new directors

First quarter 2021 earnings released: US$0.49 loss per share (vs US$0.54 loss in 1Q 2020)

Kala Pharmaceuticals Announces Preferred Position for Eysuvis™ on Cigna

New 90-day low: US$6.86

Full year 2020 earnings released: US$1.99 loss per share (vs US$2.76 loss in FY 2019)

Revenue misses expectations

Kala Pharmaceuticals, Inc. to Report Q4, 2020 Results on Feb 25, 2021

Kala Pharmaceuticals Announces EYSUVIS™ Now Covered by Express Scripts

Kala Pharmaceuticals, Inc. Announces Availability of EYSUVISTM for the Treatment of Dry Eye Disease and Provides Update on Development Pipeline

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento